Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum

Cell(2021)10.1016/j.cell.2021.06.020Source: DataRank Database

Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum is a research paper published in Cell (2021). On theSindex it has a DataRank of 0. It has been cited 750 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access750 citations

Download PDF

Cite:

Linked data & code

gen nct pdb doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (41 grants)Impact (FWCI 44.17)OA: hybridTopics (84)Linked Datasets (8)DataCite Reuse (8)IDs (PubMed, PMC, OpenAlex)Annotations (4)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (59)

Helen M. Ginn ORCID,Wanwisa Dejnirattisai ORCID,Piyada Supasa ORCID,Beibei Wang ORCID,Aekkachai Tuekprakhon ORCID

Live enrichment

PubMed:34242578 PMC:PMC8218332 OpenAlex:https://openalex.org/W3172858351

Wellcome Trust

Grant: GB-CHC-210183

Wellcome Trust

Grant: 203141/Z/16/Z

Wellcome Trust

Grant: 101122/Z/13/Z

Wellcome Trust

Grant: 090532/Z/09/Z

National Institutes of Health

Grant: U19 I082360

Bill and Melinda Gates Foundation

Grant: INV-016202

Medical Research Council

Grant: MC_PC_20016

HICC: Humoral Immune Correlates for COVID19: Defining protective responses and critical readouts for Clinical Trials of Vaccines and Therapeutics

Medical Research Council

Grant: MC_PC_19060

nCoV: Developing CoV-bnMABs for therapy of highly pathogenic coronaviruses including SARS-CoV-2

Fundação Oswaldo Cruz

Grant: VPPCB-007-FIO-18-2-30

Cancer Research UK

Grant: C375/A17721

Department of Health and Social Care

Grant: PCT/GB2012/000467

Wellcome Trust

Grant: 203224/Z/16/Z

Medical Research Council

Grant: MC_UU_00008/11

Medical Research Council

Grant: MR/N00065X/1

Structural Studies on Viruses, Viral Proteins and Cell Interactions

National Institute for Health Research (NIHR)

Grant: NIHR300791

Wellcome Trust

Grant: 109965/Z/15/Z

National Institute for Health Research (NIHR)

Grant: CL-2018-13-007

National Institute for Health Research (NIHR)

Grant: COV19OxfordVaccine01

Medical Research Council

Grant: MR/V028448/1

National Institute for Health Research (NIHR)

Grant: COV0170

Medical Research Council

Grant: G1001046

National Institute for Health Research (NIHR)

Grant: CL-2020-13-002

Medical Research Council

Grant: G0600520

Wellcome Trust

Grant: 210183

Sex differences in macrophage dynamic behaviours

Medical Research Council

Grant: MC_PC_19055

Medical Research Council

Grant: MR/L018942/1

Medical Research Council

Grant: MR/V001329/1

National Institute for Health Research (NIHR)

Grant: NF-SI-0515-10005

National Institute for Health Research (NIHR)

Grant: NF-SI-0617-10139

Wellcome Trust

Grant: 090532

Understanding the genetic basis of common human diseases: core funding for the Wellcome Trust Centre for Human Genetics.

Wellcome Trust

Grant: 109965

Function of novel human T cell subsets in host defence

Wellcome Trust

Grant: 203141

Human Genetics and Disease Biology: Core Renewal for the Wellcome Trust Centre for Human Genetics

Wellcome Trust

Grant: 101122

Improved control of endemic foot-and-mouth disease by development of virus like particle vaccines

Coalition for Epidemic Preparedness Innovations

Public Health England

Chinese Academy of Medical Sciences

Conselho Nacional de Desenvolvimento Científico e Tecnológico

Fundação de Amparo à Pesquisa do Estado do Amazonas

NIHR Oxford Biomedical Research Centre

National Institute for Health Research (NIHR)

UK Research and Innovation

FWCI

44.17

Citation Percentile

1.0%

Influential Citations

Citation Trend

2020

2021

2022

2023

2024

2025

2026

hybridLicense: cc-by

journalhttp://www.cell.com/article/S0092867421007558/pdf

HYBRIDhttp://www.cell.com/article/S0092867421007558/pdf

publisherhttp://www.cell.com/article/S0092867421007558/pdf

publisherhttps://api.elsevier.com/content/article/PII:S0092867421007558?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0092867421007558?httpAccept=text/plain

Fields of Study

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesSARS-CoV-2 detection and testingMedicine0301 basic medicine03 medical and health sciences0303 health sciencesAnimalsAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralAntigen-Antibody ComplexCOVID-19COVID-19 VaccinesChlorocebus aethiopsCrystallography, X-RayHumansImmunization, PassiveNeutralization TestsProtein DomainsSARS-CoV-2Spike Glycoprotein, CoronavirusVero CellsCOVID-19 Serotherapy

MeSH Terms

Protein DomainsCOVID-19SARS-CoV-2COVID-19 VaccinesCOVID-19 SerotherapyAnimalsAntibodies, MonoclonalAntibodies, ViralAntigen-Antibody ComplexChlorocebus aethiopsHumansImmunization, PassiveNeutralization TestsVero CellsCrystallography, X-RayAntibodies, NeutralizingSpike Glycoprotein, Coronavirus

Keywords

BiologyNeutralizationVirologyAntibodyAntigenImmunizationVirusImmunologyStructureVariantVaccineEscapeSars-cov-2Receptor-binding-domainB.1.617Delta VariantCOVID-19 VaccinesAntigen-Antibody ComplexCoronavirus Disease 2019 ResearchFOS: Health sciencesAntibodies, ViralCrystallography, X-RayDiagnostic Methods for COVID-19 DetectionArticleCoronavirus Disease 2019Protein DomainsNeutralization TestsChlorocebus aethiopsHealth SciencesAnimalsHumansVero CellsCOVID-19 SerotherapyQR355VaccinesFOS: Clinical medicineImmunization, PassiveAntibodies, MonoclonalCOVID-19Antibodies, NeutralizingInfectious DiseasesSpike Glycoprotein, CoronavirusMedicine

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

Additional file 1 of Sequential immunization with SARS-CoV-2 RBD vaccine induces potent and broad neutralization against variants in mice

10.6084/m9.figshare.17870746figshare

Additional file 1 of Sequential immunization with SARS-CoV-2 RBD vaccine induces potent and broad neutralization against variants in mice

10.6084/m9.figshare.17870746.v1figshare

Additional file 1 of Identification and application of a pair of noncompeting monoclonal antibodies broadly binding to the nucleocapsid proteins of SARS-CoV-2 variants including Omicron

10.6084/m9.figshare.19923241.v1figshare

Additional file 1 of Identification and application of a pair of noncompeting monoclonal antibodies broadly binding to the nucleocapsid proteins of SARS-CoV-2 variants including Omicron

10.6084/m9.figshare.19923241figshare

Additional file 1 of Neutralizing monoclonal antibody in patients with coronavirus disease 2019: an observational study

10.6084/m9.figshare.22609760.v1figshare

Additional file 1 of Neutralizing monoclonal antibody in patients with coronavirus disease 2019: an observational study

10.6084/m9.figshare.22609760figshare

Additional file 1 of Immune Dysregulation in SARS-CoV-2 patients coinfected with Mycobacterium tuberculosis (Mtb) or HIV in China

10.6084/m9.figshare.25271739.v1figshare

Additional file 1 of Immune Dysregulation in SARS-CoV-2 patients coinfected with Mycobacterium tuberculosis (Mtb) or HIV in China

10.6084/m9.figshare.25271739figshare